PDF herunterladen
Semin Thromb Hemost 2008; 34(1): 086-096
DOI: 10.1055/s-2008-1066027
© Thieme Medical Publishers

The Laboratory Diagnosis and Clinical Management of Patients with Heparin-Induced Thrombocytopenia: An Update

Margaret Prechel1 , Jeanine M. Walenga2
  • 1Assistant Professor, Department of Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois
  • 2Professor, Departments of Thoracic & Cardiovascular Surgery and Pathology, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. April 2008 (online)

   Lizenzen und Reprints

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is a serious adverse effect of heparin exposure that can progress to severe thrombosis, amputation, or death. HIT is an immune response in which antibodies cause platelet activation, platelet aggregation, the generation of procoagulant platelet microparticles, and activation of leukocytes and endothelial cells. Early diagnosis based on a comprehensive interpretation of clinical and laboratory information is important to improve clinical outcomes. However, limitations of the laboratory assays and atypical clinical presentations can make the diagnosis difficult. Clinical management of patients with HIT is with a non-heparin anticoagulant such as a direct thrombin inhibitor or danaparoid followed by a vitamin K antagonist for long-term treatment. The new anti-factor Xa drugs (fondaparinux, rivaroxaban, apixaban) and other non-heparin antithrombotic agents can potentially be used for the treatment of HIT if clinically validated. Important drug-specific limitations and dosing and monitoring guidelines must be respected for patient safety. Issues still exist regarding the optimal clinical management of HIT.

KEYWORDS

Heparin - thrombocytopenia - antibody - assays - thrombin inhibitor

REFERENCES

  • 1 Kelton J G, Sheridan D, Santos A et al.. Heparin-induced thrombocytopenia: laboratory studies.  Blood. 1988;  72 925-930
    PubMedSuche in Google Scholar
  • 2 Amiral J, Bridey F, Dreyfus M et al.. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.  Thromb Haemost. 1992;  68 95-96
    Thieme ConnectPubMedSuche in Google Scholar
  • 3 Greinacher A, Potzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen.  Thromb Haemost. 1994;  71 247-251
    CrossrefPubMedSuche in Google Scholar
  • 4 Maccarana M, Lindahl U. Model of interaction between platelet factor 4 and heparin.  Glycobiology. 1993;  3 271-277
    PubMedSuche in Google Scholar
  • 5 Mayo K H, Ilyina E, Roongta V et al.. Heparin binding to platelet factor-4. An NMR and site-directed mutagenesis study: arginine residues are crucial for binding.  Biochem J. 1995;  312 357-365
    PubMedSuche in Google Scholar
  • 6 Newman P M, Chong B H. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation.  Blood. 2000;  96 182-187
    PubMedSuche in Google Scholar
  • 7 Suh J S, Aster R H, Visentin G P. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis recognize different epitopes on heparin:platelet factor 4.  Blood. 1998;  91 916-922
    PubMedSuche in Google Scholar
  • 8 Visentin G P. Heparin-induced thrombocytopenia: molecular pathogenesis.  Thromb Haemost. 1999;  82 448-456
    PubMedSuche in Google Scholar
  • 9 Rauova L, Poncz M, McKenzie S E et al.. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.  Blood. 2005;  105 131-138
    CrossrefPubMedSuche in Google Scholar
  • 10 Visentin G P, Ford S E, Scott P J, Aster R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.  J Clin Invest. 1994;  93 81-88
    CrossrefPubMedSuche in Google Scholar
  • 11 Newman P M, Chong W J. Further characterization of antibody and antigen in heparin-induced thrombocytopenia.  Br J Haematol. 1999;  107 303-309
    CrossrefPubMedSuche in Google Scholar
  • 12 Amiral J, Marfaing-Koka M, Wolf M et al.. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia.  Blood. 1996;  88 410-416
    PubMedSuche in Google Scholar
  • 13 Regnault V, deMaistre E, Carteaux J, Gruel Y, Nguyen P. Platelet activation induced by human antibodies to interleukin-8.  Blood. 2003;  101 1419-1421
    CrossrefPubMedSuche in Google Scholar
  • 14 Walenga J M, Prechel M M, Jeske W P, Bakhos M. Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia.  Curr Opin Pulm Med. 2005;  11 385-391
    CrossrefPubMedSuche in Google Scholar
  • 15 Fareed J, Bick R L, Rao G et al.. The immunogenic potential of generic versions of low-molecular weight heparins may not be the same as the branded products.  Clin Appl Thromb Hemost. 2008;  14 5-7
    CrossrefPubMedSuche in Google Scholar
  • 16 Jeske W P, Walenga J M, Szatkowski E et al.. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.  Thromb Res. 1997;  88 271-281
    CrossrefPubMedSuche in Google Scholar
  • 17 Warkentin T E, Hayward C P, Boshkov L K et al.. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.  Blood. 1994;  84 3691-3699
    CrossrefPubMedSuche in Google Scholar
  • 18 Walenga J M, Jeske W P, Prechel M M, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia.  Semin Thromb Hemost. 2004;  30(Suppl 1) 57-67
    Thieme ConnectPubMedSuche in Google Scholar
  • 19 Jeske W P, Vasaiwala S, Schlenker R, Wallis E, Walenga J M. Leukocyte activation in heparin-induced thrombocytopenia.  Blood. 2000;  96 29b
    PubMedSuche in Google Scholar
  • 20 Pouplard C, Iochmann S, Renard B et al.. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia.  Blood. 2001;  97 3300-3302
    CrossrefPubMedSuche in Google Scholar
  • 21 Herbert J M, Savi P, Jeske W P, Walenga J M. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells.  Thromb Haemost. 1998;  80 326-331
    PubMedSuche in Google Scholar
  • 22 Walenga J M, Michal K, Hoppensteadt D, Wood J J, Bick R L, Robinson J A. Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome.  Clin Appl Thromb Hemost. 1999;  5(Suppl 1) S76-S84
    CrossrefPubMedSuche in Google Scholar
  • 23 Fareed J, Walenga J M, Hoppensteadt D A et al.. Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation.  Semin Thromb Hemost. 1999;  25(Suppl 1) 37-42
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Blank M, Shoenfeld Y, Tavor S et al.. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells.  Int Immunol. 2002;  14 121-129
    CrossrefPubMedSuche in Google Scholar
  • 25 Matsuo T, Tomaru T, Kario K, Hirokawa T. Incidence of heparin-PF4 complex antibody formation and heparin-induced thrombocytopenia in acute coronary syndrome.  Thromb Res. 2005;  115 475-481
    CrossrefPubMedSuche in Google Scholar
  • 26 Opatrny L, Warner M N. Risk of thrombosis in patients with malignancy and heparin-induced thrombocytopenia.  Am J Hematol. 2004;  76 240-244
    CrossrefPubMedSuche in Google Scholar
  • 27 Reininger C B, Greinacher A, Graf J, Lassila R, Steckmeier B, Schwieberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin.  Thromb Res. 1996;  81 641-649
    CrossrefPubMedSuche in Google Scholar
  • 28 Warkentin T E, Sheppard J A, Horsewood P, Simpson P J, Moore J C. Impact of the patient population on the risk for heparin-induced thrombocytopenia.  Blood. 2000;  96 1703-1708
    CrossrefPubMedSuche in Google Scholar
  • 29 Shuster T A, Silliman W R, Coats R D, Mureebe L, Silver D. Heparin-induced thrombocytopenia: twenty-nine years later.  J Vasc Surg. 2003;  38 1316-1322
    CrossrefPubMedSuche in Google Scholar
  • 30 Warkentin T E, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention.  Chest. 2004;  126 311S-337S
    CrossrefPubMedSuche in Google Scholar
  • 31 Warkentin T E, Crowther M A. When is HIT really HIT?.  Ann Thorac Surg. 2007;  83 21-23
    CrossrefPubMedSuche in Google Scholar
  • 32 Lo G K, Juhl D, Warkentin T E, Sigouin C S, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings.  J Thromb Haemost. 2006;  4 759-765
    CrossrefPubMedSuche in Google Scholar
  • 33 Pouplard C, Amiral J, Borg J Y, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia.  Am J Clin Pathol. 1999;  111 700-706
    PubMedSuche in Google Scholar
  • 34 Parker R I. Measurement of heparin-dependent platelet antibodies in the diagnosis of heparin-induced thrombocytopenia: fact or fiction?.  Crit Care Med. 2007;  35 1784-1785
    CrossrefPubMedSuche in Google Scholar
  • 35 Walenga J M, Jeske W P, Fasanella A R, Wood J J, Bakhos M. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia.  Semin Thromb Hemost. 1999;  25(Suppl. 1) 43-49
    PubMedSuche in Google Scholar
  • 36 Chong B H, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia.  Thromb Haemost. 1993;  69 344-350
    Thieme ConnectPubMedSuche in Google Scholar
  • 37 Warkentin T E, Hayward C PM, Smith C A, Kelly P M, Kelton J G. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia.  J Lab Clin Med. 1992;  120 371-379
    PubMedSuche in Google Scholar
  • 38 Eichler P, Budde U, Haas S et al.. First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA.  Thromb Haemost. 1999;  81 625-629
    Thieme ConnectPubMedSuche in Google Scholar
  • 39 Izban K F, Lietz J W, Hoppensteadt D A et al.. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia.  Semin Thromb Hemost. 1999;  25(Suppl 1) 51-56
    PubMedSuche in Google Scholar
  • 40 Warkentin T E, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A Heparin-Induced Thrombocytopenia. 4th ed. New York, NY; Informa Healthcare 2007: 227-260
    Suche in Google Scholar
  • 41 Martin-Toutain I, Piette J C, Diemert M C, Faucher C, Jobic L, Ankri A. High prevalence of antibodies to platelet factor 4 heparin in patients with antiphospholipid antibodies in absence of heparin-induced thrombocytopenia.  Lupus. 2007;  16 79-83
    CrossrefPubMedSuche in Google Scholar
  • 42 Warkentin T E, Sheppard J A, Moore J C, Moore K M, Sigouin C S, Kelton J G. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class to we need?.  J Lab Clin Med. 2005;  146 341-346
    CrossrefPubMedSuche in Google Scholar
  • 43 Juhl D, Eichler P, Lubenow N, Strobel U, Wessel A, Greinacher A. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patients samples referred for diagnostic testing for heparin-induced thrombocytopenia.  Eur J Haematol. 2006;  76 420-426
    CrossrefPubMedSuche in Google Scholar
  • 44 Amiral J, Bridey F, Dreyfus M et al.. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.  Thromb Haemost. 1992;  68 95-96
    Thieme ConnectPubMedSuche in Google Scholar
  • 45 Platelet Immunology ISTH Scientific Subcommittee .Chairs: Warkentin T, Chong B, Greinacher A, Gruel Y, Kiefel V, Kroll H. 6 July 2007. Palexpo, Geneva, Switzerland. http://Available at www.isth2007.com. Accessed December 6, 2007
    Suche in Google Scholar
  • 46 Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S. Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia.  J Thromb Haemost. 2007;  5 1373-1379
    CrossrefPubMedSuche in Google Scholar
  • 47 Warkentin T E. Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia.  Arch Pathol Lab Med. 2002;  126 1415-1423
    PubMedSuche in Google Scholar
  • 48 Zwicker J I, Uhl L, Huang W-Y, Shaz B H, Bauer K A. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.  J Thromb Haemost. 2004;  2 2133-2137
    CrossrefPubMedSuche in Google Scholar
  • 49 Refaai M A, Laposata M, VanCott E M. Clinical significance of a borderline titer in a negative ELISA test for heparin-induced thrombocytopenia.  Am J Clin Pathol. 2003;  119 61-65
    CrossrefPubMedSuche in Google Scholar
  • 50 Smythe M A, Koerber J M, Mattson J C. An evaluation of heparin platelet factor 4 antibody testing.  J Thromb Haemost. 2005;  3(Suppl 1) 1516
    PubMedSuche in Google Scholar
  • 51 Messmore H L, Jeske W P, Wehrmacher W, Walenga J M. Benefit-risk assessment of treatments for heparin-induced thrombocytopenia.  Drug Safety. 2003;  26 625-641
    CrossrefPubMedSuche in Google Scholar
  • 52 Wallis D E, Workman D L, Lewis B F, Pifarré R, Moran J F. Failure of early heparin cessation as a treatment for heparin-induced thrombocytopenia.  Am J Med. 1999;  106 629-635
    CrossrefPubMedSuche in Google Scholar
  • 53 Lewis B E, Wallis D E, Berkowitz S D for the ARG-911 Study Investigators et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103 1838-1843
    CrossrefPubMedSuche in Google Scholar
  • 54 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton J G. for the Argatroban-915 Investigators. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163 1849-1856
    CrossrefPubMedSuche in Google Scholar
  • 55 Greinacher A, Völpel H, Janssens U et al.. for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study.  Circulation. 1999;  99 73-80
    CrossrefPubMedSuche in Google Scholar
  • 56 Greinacher A, Janssens U, Berg G for the HAT Investigataors et al.. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia.  Circulation. 1999;  100 587-593
    CrossrefPubMedSuche in Google Scholar
  • 57 Walenga J M, Fasanella A R, Iqbal O et al.. Coagulation laboratory testing in patients treated with argatroban.  Semin Thromb Hemost. 1999;  25(Suppl 1) 61-66
    PubMedSuche in Google Scholar
  • 58 Walenga J M, Drenth A F, Mayuga M et al.. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing.  Clin Appl Thromb Hemost. 2008;  , in press
    PubMedSuche in Google Scholar
  • 59 Hirsh J, Heddle N, Kelton J G. Treatment of heparin-induced thrombocytopenia.  Arch Intern Med. 2004;  164 361-369
    CrossrefPubMedSuche in Google Scholar
  • 60 Warkentin T E. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban.  Thromb Res. 2003;  110 73-82
    CrossrefPubMedSuche in Google Scholar
  • 61 Walenga J M, Fareed D, Schultz C, Neville B, Hoppensteadt D. Argatroban, not lepirudin or bivalirudin, treatment results in the generation of nitric oxide during parenteral administration.  Blood. 2004;  104 512a
    PubMedSuche in Google Scholar
  • 62 Lewis B E, Walenga J M, Hursting M J. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Cardiovasc Rev Rep. 2002;  23 445-457
    PubMedSuche in Google Scholar
  • 63 Swan S K, Hursting M J. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction.  Pharmacotherapy. 2000;  20 318-329
    CrossrefPubMedSuche in Google Scholar
  • 64 Swan S K, St. Peter J V, Lambrecht L J, Hursting M J. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects.  Pharmacotherapy. 2000;  20 756-770
    CrossrefPubMedSuche in Google Scholar
  • 65 La Monte M P, Brown P M, Hursting M J. Alternative parenteral anticoagulation with argatroban, a direct thrombin inhibitor.  Expert Rev Cardiovasc Ther. 2005;  3 31-41
    CrossrefPubMedSuche in Google Scholar
  • 66 Matthai Jr W H, Hursting M J, Lewis B E, Kelton J G. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia.  Thromb Res. 2005;  116 121-126
    CrossrefPubMedSuche in Google Scholar
  • 67 Walenga J M, Ahmad S, Hoppensteadt D, Iqbal O, Hursting M J, Lewis B E. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.  Thromb Res. 2002;  105 401-405
    CrossrefPubMedSuche in Google Scholar
  • 68 Lewis B E, Matthai W H, Cohen M, Moses J, Hursting M J, Leya F. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
    CrossrefPubMedSuche in Google Scholar
  • 69 Jang I K, Hurstings M J. When heparins promote thrombosis: review of heparin-induced thrombocytopenia.  Circulation. 2005;  111 2671-2683
    CrossrefPubMedSuche in Google Scholar
  • 70 Cetta F, Graham L C, Wrona L L, Arruda M J, Walenga J M. Argatroban use during pediatric interventional cardiac catheterization.  Catheter Cardiovasc Interv. 2004;  61 147-149
    CrossrefPubMedSuche in Google Scholar
  • 71 Jang I K, Lewis B E, Matthai W H, Kleiman N S. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study.  J Thromb Thrombolysis. 2004;  18 31-37
    CrossrefPubMedSuche in Google Scholar
  • 72 LaMonte M P, Brown P M, Hursting M J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.  Crit Care Med. 2004;  32 976-980
    CrossrefPubMedSuche in Google Scholar
  • 73 Cochran K, DeMartini T J, Lewis B E et al.. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.  J Invasive Cardiol. 2003;  15 617-621
    PubMedSuche in Google Scholar
  • 74 Eichler P, Friesen H J, Lubenow N, Jaeger B, Greinacher A. Anti-hirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance.  Blood. 2000;  96 2373-2378
    PubMedSuche in Google Scholar
  • 75 Greinacher A, Eichler P, Albrecht D, Strobel U, Potzsch B, Eriksson B I. Anti-hirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance.  Blood. 2003;  101 2617-2619
    CrossrefPubMedSuche in Google Scholar
  • 76 Fischer K G, Liebe V, Hudek R et al.. Anti-hirudin antibodies alter pharmacokinetics and pharmacodynamics of recombinant hirudin.  Thromb Haemost. 2003;  89 973-982
    PubMedSuche in Google Scholar
  • 77 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT).  Circulation. 2003;  108 2062-2065
    CrossrefPubMedSuche in Google Scholar
  • 78 Mahaffey K W, Lewis B E, Wildermann N M for the ATBAT Investigators et al. The anticoagulant therapy with bivalirudin to assist in the performance of PCI in patients with heparin-induced thrombocytopenia (ATBAT) study.  J Invasive Cardiol. 2003;  15 611-616
    PubMedSuche in Google Scholar
  • 79 Merry A F, Raudkivi P J, Middleton N G et al.. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery.  Ann Thorac Surg. 2004;  77 925-931
    CrossrefPubMedSuche in Google Scholar
  • 80 Koster A, Spiess B, Chew D P et al.. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting.  Am J Cardiol. 2004;  93 356-359
    CrossrefPubMedSuche in Google Scholar
  • 81 Pötzsch B, Klovekorn W P. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia.  N Engl J Med. 2000;  343 515-516
    CrossrefPubMedSuche in Google Scholar
  • 82 Magnani H N, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004.  Thromb Haemost. 2006;  95 967-981
    Thieme ConnectPubMedSuche in Google Scholar
  • 83 Lindhoff-Last E, Kreutzenbeck H-J, Magnani H N. Treatment of 51 pregnancies with danaparoid because of heparin intolerance.  Thromb Haemost. 2005;  93 63-69
    PubMedSuche in Google Scholar
  • 84 Chong B H, Gallus A S, Cade J F, Magnani H, Manoharan A, Oldmeadow M. for the Australian HIT Study Group . Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis.  Thromb Haemost. 2001;  86 1170-1175
    PubMedSuche in Google Scholar
  • 85 Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia.  Thromb Haemost. 2001;  85 950-957
    Thieme ConnectPubMedSuche in Google Scholar
  • 86 Walenga J M, Koza M J, Lewis B E, Pifarré R. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents.  Clin Appl Thromb Hemost. 1996;  2(Suppl 1) S21-S27
    PubMedSuche in Google Scholar
  • 87 Elalamy I, Lecrubier C, Horellou M H, Conard J, Samama M M. Heparin-induced thrombocytopenia: laboratory management.  Ann Med. 2000;  32(Suppl 1) 60-67
    PubMedSuche in Google Scholar
  • 88 Wallis D E, Quintos R, Wehrmacher W, Messmore H L. Safety of warfarin anticoagulation in patients with heparin-induced thrombocytopenia.  Chest. 1999;  116 1333-1338
    CrossrefPubMedSuche in Google Scholar
  • 89 Gosselin R C, Dager W E, King J H et al.. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values.  Am J Clin Pathol. 2004;  121 593-599
    CrossrefPubMedSuche in Google Scholar
  • 90 Sheth S B, DiCicco R A, Hursting M J, Montague T, Jorkasky D K. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin.  Thromb Haemost. 2001;  85 435-440
    PubMedSuche in Google Scholar
  • 91 Harder S, Graff J, Klinkhardt U et al.. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on PT, aPTT, and ecarin clotting time.  Thromb Haemost. 2004;  91 1137-1145
    PubMedSuche in Google Scholar
  • 92 Hursting M J, Lewis B E, Macfarlane D E. Transitioning from argatroban to warfarin therapy in patients with heparin-induced thrombocytopenia.  Clin Appl Thromb Hemost. 2005;  11 279-287
    CrossrefPubMedSuche in Google Scholar
  • 93 Parody R, Oliver A, Souto J C, Fontcuberta J. Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.  Haematologica. 2003;  88 ECR32
    PubMedSuche in Google Scholar
  • 94 D'Amico E A, Villaca P R, Gualandro S F, Bassitt R P, Chamone D A. Successful use of Arixtra in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia.  J Thromb Haemost. 2003;  1 2452-2453
    CrossrefPubMedSuche in Google Scholar
  • 95 Bradner J, Hallisey R K, Kuter D J. Fondaparinux in the treatment of heparin-induced thrombocytopenia.  Blood. 2004;  104 , abstract 1775
    PubMedSuche in Google Scholar
  • 96 Warkentin T E, Maurer B T, Aster R H. Heparin-induced thrombocytopenia associated with fondaparinux.  N Engl J Med. 2007;  356 2653-2655
    CrossrefPubMedSuche in Google Scholar
  • 97 Warkentin T E, Cook R J, Marder V J et al.. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.  Blood. 2005;  106 3791-3796
    CrossrefPubMedSuche in Google Scholar
  • 98 Walenga J M, Jeske W P, Wallis D E et al.. Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.  Semin Thromb Hemost. 1999;  25(Suppl 1) 77-81
    PubMedSuche in Google Scholar
  • 99 Walenga J M, Lewis B E, Jeske W P et al.. Combined thrombin and platelet inhibition treatment for HIT patients.  Haemostaseologie. 1999;  19 128-133
    PubMedSuche in Google Scholar
  • 100 Haas S, Walenga J M, Jeske W P, Fareed J. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications.  Semin Thromb Hemost. 1999;  25(Suppl 1) 67-75
    PubMedSuche in Google Scholar

Dr. Jeanine M Walenga

Cardiovascular Institute, Building 110

Room 5226, Loyola University Medical Center, Maywood, IL 60153

eMail: jwaleng@lumc.edu